# OnCo record nct05318469 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05318469/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05318469", "NCT05318469" ;
  schema:name "Ivermectin with balstilimab or pembrolizumab in metastatic triple-negative breast cancer (Cedars-Sinai phase 1/2)"@en ;
  schema:description "A small single-centre trial in Los Angeles is testing whether adding a worm medicine to an immunotherapy antibody is safe, and then whether it shrinks triple-negative breast cancer that has spread. It opened in 2023 and has not reported."@en ;
  schema:url <https://onco.cc/trials/nct05318469/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05318469>, <https://clinicaltrials.gov/study/NCT07487805> ;
  onco:status "recruiting" ;
  onco:phase "1/2" ;
  onco:cancers <https://onco.cc/cancers/tnbc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/drug-repurposing/> ;
  onco:drugs <https://onco.cc/drugs/ivermectin/>, <https://onco.cc/drugs/balstilimab/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/agenus/>, <https://onco.cc/companies/merck/> ;
  onco:institutions <https://onco.cc/institutions/cedars-sinai-cancer/> ;
  onco:terms <https://onco.cc/terms/rp2d/>, <https://onco.cc/terms/orr/>, <https://onco.cc/terms/single-arm/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-generic-repurposing/> .